Table III.
PFS and OS analysis with the Kaplan-Meier method and log-rank test.
| Clinical characteristic | Clinical factors | Patients (n) | Median PFS (days) | 95% CI | P-valuea | Median OS (days) | 95% CI | P-valuea |
|---|---|---|---|---|---|---|---|---|
| MB rs7292 | CC | 8 | 71.0 | 50.2–91.8 | 0.001 | 244.0 | 132.4–355.6 | 0.245 |
| CT+TT | 100 | 179.0 | 162.7–191.1 | 465.0 | 302.8–627.2 | |||
| ABCG2 rs2231142 | AA | 13 | 182.0 | 159.2–204.7 | 0.705 | 297.0 | 173.2–420.8 | 0.278 |
| AC+CC | 94 | 173.0 | 152.3–193.7 | 465.0 | 292.0–638.0 | |||
| MLH1 rs1800734 | AA | 35 | 159.0 | 112.0–206.0 | 0.897 | 367.0 | 50.3–683.7 | 0.590 |
| AG+GG | 73 | 179.0 | 158.5–199.5 | 465.0 | 309.3–620.7 | |||
| MLH1 rs9852810 | AA+AG | 14 | 147.0 | 51.7–242.3 | 0.040 | 241.0 | 100.0–382.1 | 0.287 |
| GG | 93 | 178.0 | 155.8–200.2 | 465.0 | 207.7–622.3 | |||
| PARP-1 rs1136410 | CC | 17 | 202.0 | 158.0–246.0 | 0.528 | 1378.0 | b | 0.156 |
| CT+TT | 90 | 169.0 | 148.1–189.9 | 403.0 | 252.4–533.6 |
a
P-value of the log-rank test.
b
95% CI cannot be calculated due to the fact that 10 out of 17 patients in the subgroup are censored. OS, overall survival time; PFS, progression-free survival; MB, myoglobin; ABCG2, ATP binding cassette subfamily G member 2; MLH1, MutL homolog 1; PARP-1, Poly(ADP-ribose) polymerase 1; UTR, untranslated region.